Embracing change together.

When the time comes to adapt, we’ll give you the confidence to make the positive changes that will have a sustainable impact on your business.



It’s a conversation not a presentation.

Taking the time to sit down and let the client talk is when true ideation happens. Perhaps there is a challenge that they can’t find a solution to, or maybe the issue first identified is deeper than first thought. By starting with an open dialogue, we become part of the solution.



Great minds inspire positive change.

We tap into your organisation’s greatest asset – it’s people. This grants us broader, richer insights and allows a 360° view of the challenges your team faces. By involving and engaging key members of your company at this stage we have a greater chance of success in the implementation phase.



Being bold and brave with our solutions.

Each organisation has a unique set of circumstances, which is why an off-the-peg solution rarely works. Our team will work closely with you to ensure they develop the right solution to the right problem. We then become a support structure to ensure you have the correct resource to reach your business goals.



Cultivating relationships that outlast the project.

Solving problems is what excites us the most. A finished project with a client who is self-sustainable is what success looks like to Grovelands. As the market pivots, we welcome the opportunity to return with new insights and additional value that complements previous projects.

Contact us

Ready to connect with us?

Get in touch

Our People

We're not your average consulting company.

We look ahead to identify opportunities that others might overlook and value long-term partnerships over swift financial wins.

Meet the team

What our clients say...

Grovelands is different to many other consulting businesses. They value the importance of building genuine long term relationships and have deep sector knowledge far beyond what I have experienced with other organisations.

Infrastructure Transition Leader

£5 billion Biotech Company